Journal Article

Spectrum of antibiotic resistance of the Spain<sup>14</sup>-5 <i> Streptococcus pneumoniae</i> clone over a 22 year period

Emilio Pérez-Trallero, José María Marimón, Alberto Gonzalez, Diego Vicente and José María García-Arenzana

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 53, issue 4, pages 620-625
Published in print April 2004 | ISSN: 0305-7453
Published online April 2004 | e-ISSN: 1460-2091 | DOI: http://dx.doi.org/10.1093/jac/dkh109
Spectrum of antibiotic resistance of the Spain14-5  Streptococcus pneumoniae clone over a 22 year period

Show Summary Details

Preview

Objective: To study the characteristics and the evolution through time of a single Streptococcus pneumoniae multidrug-resistant international clone.

Methods: From 1981 to 2002, the presence of the multidrug-resistant Spain14-5 clone was studied among the 4201 S. pneumoniae isolated in Gipuzkoa (northern Spain).

Results: Overall, 93 isolates belonging to the Spain14-5 clone were identified. The first isolate of this clone was detected in 1981 and was already resistant to β-lactams, erythromycin, clindamycin and chloramphenicol. The reference strain from the international collection for this clone was susceptible to macrolides and lincosamides whereas most of the isolates studied, including the first isolate detected in 1981, were resistant to macrolides and had the erm(B) gene encoding macrolide resistance.

Conclusions: The clone was genetically stable through time, was multiresistant since its inception and has recently become highly resistant to fluoroquinolones. The characteristic antibiotic resistance pattern of this clone should include erythromycin resistance.

Keywords: Keywords: multiresistance, PFGE, MLST, fluoroquinolone resistance, macrolide resistance

Journal Article.  4927 words.  Illustrated.

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.